- 12Feb, 2026
February 10, 2026 — TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of Directors. TAXIS Pharmaceuticals, a clinical-stage company focused on developing investigational therapies to combat multidrug-resistant bacterial infections and address antimicrobial resistance [...]
Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point. While US government prioritisation of AMR will likely remain low in 2026, the EU and Australia are ramping up incentives and R&D funding. [...]
Charting The Future Of Antimicrobial Resistance
A conversation with Ajit Parhi, Ph.D., chief scientific officer, TAXIS Pharmaceuticals Antimicrobial resistance (AMR) poses a grave threat to global public health and is estimated to cause around 10 million deaths each year by 2050if not addressed. While U.S. government prioritization of AMR is likely [...]
Clinical Leader: The Rise Of Antimicrobial Resistance And Strategic Research Imperatives For 2026
By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals The ground beneath our feet is shifting. The foundational promise of modern medicine — that bacterial infections are a solvable problem – is being severely tested by an accelerating crisis: antimicrobial resistance (AMR). 2025 brought [...]
- 27Oct, 2025
US infections caused by NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE) increased by more than 460% from 2019 to 2023, according to a Centers for Disease Control and Prevention (CDC) analysis published in Annals of Internal Medicine. CDC cautions that this surge could raise overall carbapenem-resistant Enterobacterales (CRE) infections [...]
- 25Sep, 2025
September 25, 2025 — TAXIS Pharmaceuticals today issued a statement in response to a new report from the Centers for Disease Control and Prevention (CDC), published in the Annals of Internal Medicine on September 23. The CDC report highlights a dramatic increase in infections caused [...]
- 10Sep, 2025
Podcast Interview: The Bio Report: Overcoming Antibiotic Resistance Listen to the podcast here. Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. One particular area of concern is drug-resistant gonorrhea, where existing therapies are being exhausted. Taxis Pharmaceuticals is [...]
